{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-21-000047","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2021-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.592605+00:00","generated_at":"2026-06-28T21:24:51.465458+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CMO Noah Rosenberg to step down Dec 31, 2021; to serve as executive advisor through 2022","bullets":["Noah Rosenberg will transition from CMO to executive advisor effective Dec 31, 2021.","He will continue as CMO until year-end, then advise through 2022 on clinical trial oversight and regulatory submissions.","Transition agreement provides severance benefits consistent with existing employment agreement.","Post-transition consulting includes monthly retainer through May 2022, hourly fees June-Dec 2022, and success bonus tied to FDA acceptance of sparsentan NDA.","Stock awards continue vesting; severance amendments extend certain benefits to 18 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-21-000047","json":"https://secwatch.observer/filing/0001438533-21-000047.json","markdown":"https://secwatch.observer/filing/0001438533-21-000047.md","text":"https://secwatch.observer/filing/0001438533-21-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853321000047/0001438533-21-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853321000047/tvtx-20211012.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T21:24:51.465458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2506e4fda7","claim":"Noah Rosenberg changed role as executive advisor at Travere Therapeutics, Inc..","evidence_excerpt":"On October 12, 2021, Travere Therapeutics, Inc. (the “Company”) announced that its chief medical officer, Noah Rosenberg, M.D., will be transitioning to an executive advisor role at the end of 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853321000047/0001438533-21-000047-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioning"},{"label":"Role","value":"executive advisor"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}